Mechanism:inhibition of DNA synthesis and to a lesser extent that of RNA and protein synthesis.
Uses superficial bladder cancer as a adjuvant in primary or recurrent pterygia.lt is usually administered by parenteral route. It does not cross blood brain barrier
Adverse effects: For a general outline see Antineoplastics. The most frequent involve the skin and mucous membranes include rash, erythema, pruritus, hyperkeratosis, alopecia, hyperpigmentation, striae, and stomatitis. Fever is also common.etc
Dosage:Adults 30 mg twice weekly in average cases, otherwise Dose can be varied between 15mg daily to 15mg weekly Total Dose 300400 mg Small cell cancer 0.25mg 05mg / kg I.V. Hodgkin's disease 0.25 0.5mg / kg I.V.,
I.M., S.C.
Vial
129 EGP
Mechanism:inhibition of DNA synthesis and to a lesser extent that of RNA and protein synthesis.
Uses superficial bladder cancer as a adjuvant in primary or recurrent pterygia.lt is usually administered by parenteral route. It does not cross blood brain barrier
Adverse effects: For a general outline see Antineoplastics. The most frequent involve the skin and mucous membranes include rash, erythema, pruritus, hyperkeratosis, alopecia, hyperpigmentation, striae, and stomatitis. Fever is also common.etc
Dosage:Adults 30 mg twice weekly in average cases, otherwise Dose can be varied between 15mg daily to 15mg weekly Total Dose 300400 mg Small cell cancer 0.25mg 05mg / kg I.V. Hodgkin's disease 0.25 0.5mg / kg I.V.,
I.M., S.C.
Note: All the provided information about this drug does not substitute for consulting a doctor.